Raiff Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Raiff Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,000	Closed	-$315K	–	35
2016 Q4	$315K	Buy	+6,000	New	+$321K	0.77%	24

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SCM

Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return

Colrain Capital Boston, Massachusetts $259M AUM 63.6% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raiff Partners's PPH Position: Q1 2017 in Review

Raiff Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2017, closing a stake of 6,000 shares — an estimated $315K sold.

Raiff Partners first reported a position in PPH in Q4 2016 and held it in 1 quarter. The position peaked at $315K in Q4 2016. 50 funds tracked by Wall St. Rank hold PPH as of Q1 2017.

Raiff Partners reported no remaining VanEck Pharmaceutical ETF position as of Q1 2017 after selling out during the quarter.
Raiff Partners sold 6,000 VanEck Pharmaceutical ETF shares in Q1 2017, an estimated $315K.
Raiff Partners first reported a position in VanEck Pharmaceutical ETF in Q4 2016 and held it in 1 quarter.
Raiff Partners's VanEck Pharmaceutical ETF position peaked at $315K in Q4 2016.
50 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2017.

Based on Raiff Partners's 13F filing for Q1 2017, filed 15 May 2017.